(Bloomberg) -- Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat products underscored the challenge to its weight-loss ...

since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, ...

Novo Nordisk (NVO) faces a 6% premarket drop after clinical trial results for its obesity drug CagriSema fell below ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its ...

Novo Nordisk (NVO) warns U.S. tariffs on pharmaceuticals may lead to drug shortages & price hikes. Read more here.

Meanwhile, Wegovy has become the go-to drug for obesity treatment, and incumbency has power in the pharmaceutical world. Even if Novo Nordisk loses considerable share to a giant like Eli Lilly and ...